Actinium grants CFO 250K stock units and 250K options

The awards have separate service-based vesting schedules, and the options expire October 14, 2036.

Rhea-AI Filing Summary

Actinium Pharmaceuticals, Inc. granted Chief Financial Officer Matthew T. David 250,000 restricted stock units (RSUs) and options to purchase 250,000 common shares on October 14, 2026, under its 2026 Employment Inducement Award Plan. Of the RSUs, 125,000 vest in three equal installments on the first, second, and third anniversaries, and 125,000 vest in full on the third anniversary; both schedules require continued service. The options have a $0.975 exercise price and expire October 14, 2036. Twenty-eight percent vest 12 months after the grant date and 2% each month thereafter, subject to continued service on each vesting date.

Insider Trade Summary

Grant/Award: 500,000 shares

Grant/Award 2 txns

Insider David Matthew T

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to purchase) F2, F3	250,000	$0.00	$0.00
Grant/Award	Common Stock F1	250,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to purchase) — 250,000 contracts (Direct); Common Stock — 250,000 shares (Direct)

Footnotes (3)

1. F1. On October 14, 2026 (the "Grant Date"), Mr. David was granted two hundred fifty thousand (250,000) Restricted Stock Units ("RSUs") under the Actinium Pharmaceuticals, Inc. 2026 Employment Inducement Award Plan (the "Inducement Plan"). One hundred twenty-five thousand (125,000) RSUs shall vest in three (3) equal installments on each of the first, second, and third anniversaries of the Grant Date, subject to Mr. David's continuing service to the Issuer on each the applicable vesting date. One hundred twenty-five thousand (125,000) RSUs shall vest in full on the third (3rd) anniversary of the Grant Date, subject to Mr. David's continuing service to the Issuer on the applicable vesting date.
2. F2. On the Grant Date, Mr. David was granted the option to purchase 250,000 shares of common stock (the "Option Grant") of Actinium Pharmaceuticals, Inc. (the "Issuer") under the Inducement Plan.
3. F3. Twenty-eight percent (28%) of the Option Grant shall vest twelve (12) months after the Grant Date and two percent (2%) of the Option Grant shall vest each month thereafter, subject to Mr. David's continuing service to the Issuer on each application vesting date.

Key Figures

RSUs granted: 250,000 RSUs Option shares: 250,000 shares Exercise price: $0.975 per share +5 more

8 metrics

RSUs granted 250,000 RSUs Granted October 14, 2026

Option shares 250,000 shares Options granted October 14, 2026

Exercise price $0.975 per share Option grant

RSUs in installment vesting schedule 125,000 RSUs Vest in three equal installments on the first, second, and third anniversaries, subject to continued service

RSUs vesting on third anniversary 125,000 RSUs Vest in full on the third anniversary, subject to continued service

Initial option vesting 28% Vests 12 months after the grant date, subject to continued service

Monthly option vesting thereafter 2% Vests each month after the initial 12-month period, subject to continued service

Option expiration October 14, 2036 Option grant

Key Terms

Restricted Stock Units, Option Grant, Inducement Plan, vest

4 terms

Restricted Stock Units financial

"granted two hundred fifty thousand (250,000) Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Option Grant financial

"the option to purchase 250,000 shares of common stock (the "Option Grant")"

Inducement Plan financial

"under the Actinium Pharmaceuticals, Inc. 2026 Employment Inducement Award Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

vest financial

"shall vest in three (3) equal installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RSUs and options did ATNM CFO Matthew T. David receive?

Matthew T. David received 250,000 RSUs and options to purchase 250,000 common shares on October 14, 2026, under Actinium Pharmaceuticals, Inc.'s 2026 Employment Inducement Award Plan.

What are the vesting terms for ATNM CFO Matthew T. David's awards?

Of the 250,000 RSUs, 125,000 vest in three equal installments on the first, second, and third anniversaries, subject to continued service; the other 125,000 vest in full on the third anniversary, also subject to continued service. For the options, 28% vest 12 months after the grant date and 2% each month thereafter, subject to continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/16/2026 - 05:11 PM EDT Accepted by SEC EDGAR 10/16/2026 - 05:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

David Matthew T

(Last) (First) (Middle)

100 PARK AVENUE, 23RD FLOOR

(Street)

NEW YORK NEW YORK 10017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Actinium Pharmaceuticals, Inc. [ ATNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	10/14/2026		A		250,000	A	$0	250,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to purchase)(2)	$0.975	10/14/2026		A		250,000		(3)	10/14/2036	Common Stock	250,000	$0	250,000	D

Explanation of Responses:

1. On October 14, 2026 (the "Grant Date"), Mr. David was granted two hundred fifty thousand (250,000) Restricted Stock Units ("RSUs") under the Actinium Pharmaceuticals, Inc. 2026 Employment Inducement Award Plan (the "Inducement Plan"). One hundred twenty-five thousand (125,000) RSUs shall vest in three (3) equal installments on each of the first, second, and third anniversaries of the Grant Date, subject to Mr. David's continuing service to the Issuer on each the applicable vesting date. One hundred twenty-five thousand (125,000) RSUs shall vest in full on the third (3rd) anniversary of the Grant Date, subject to Mr. David's continuing service to the Issuer on the applicable vesting date.

2. On the Grant Date, Mr. David was granted the option to purchase 250,000 shares of common stock (the "Option Grant") of Actinium Pharmaceuticals, Inc. (the "Issuer") under the Inducement Plan.

3. Twenty-eight percent (28%) of the Option Grant shall vest twelve (12) months after the Grant Date and two percent (2%) of the Option Grant shall vest each month thereafter, subject to Mr. David's continuing service to the Issuer on each application vesting date.

	/s/ Matthew T David	10/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)